. . . . . "29027213"^^ . "ALK-h\u00E4mmare \u00E4r l\u00E4kemedel som \u00E4r verksamma mot cancertum\u00F6rer vars \u00F6verlevnad \u00E4r beroende av (ALK). L\u00E4kemedlen tillh\u00F6r gruppen och kategoriseras i under L01ED. Den generella verkningsmekanismen f\u00F6r ALK-h\u00E4mmarna \u00E4r att binda till den delen av ALK som tillf\u00F6r energi till enzymets reaktioner genom att bryta ned ATP och p\u00E5 s\u00E5 s\u00E4tt blockera enzymets aktivitet."@sv . . . . . . . . . . . "ALK inhibitor"@en . . . . . . . . . . . . . "ALK-h\u00E4mmare"@sv . . . "1115193045"^^ . . . . . . . . . . . . . . . . "ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of tumour cells. All the current approved ALK inhibitors function by binding to the ATP pocket of the abnormal ALK protein, blocking its access to energy and deactivating it.A majority of ALK-rearranged NSCLC harbour the EML4-ALK fusion, although as of 2020, over 92 fusion partners have been discovered in ALK+ NSCLC. For each fusion partner, there can be several fusion variants depending on the position the two genes were fused at, and this may have implications on the response of the tumour and prognosis of the patient."@en . . . . . . . . . . "ALK-h\u00E4mmare \u00E4r l\u00E4kemedel som \u00E4r verksamma mot cancertum\u00F6rer vars \u00F6verlevnad \u00E4r beroende av (ALK). L\u00E4kemedlen tillh\u00F6r gruppen och kategoriseras i under L01ED. Den generella verkningsmekanismen f\u00F6r ALK-h\u00E4mmarna \u00E4r att binda till den delen av ALK som tillf\u00F6r energi till enzymets reaktioner genom att bryta ned ATP och p\u00E5 s\u00E5 s\u00E4tt blockera enzymets aktivitet."@sv . "17041"^^ . . . . . . "ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of tumour cells. All the current approved ALK inhibitors function by binding to the ATP pocket of the abnormal ALK protein, blocking its access to energy and deactivating it.A majority of ALK-rearranged NSCLC harbour the EML4-ALK fusion, although as of 2020, over 92 fusion partners have been discovered in ALK+ NSCLC. For each fusion partner, there can be several fusion variants depending on the position the two genes were fused at, and this may have implications on the response of the tumour and prognosis of the patient."@en . . . . . . . . . . . . . .